查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016396

免疫查核點抑制劑市場報告：按類型、分銷管道、應用和地區分類（2026-2034 年）

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球免疫查核點抑制劑市場規模達568億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,824億美元，2026年至2034年的複合年成長率為13.43%。多種癌症的盛行率上升、呼吸系統疾病發生率增加以及人們對個人化醫療日益成長的興趣是推動該市場成長的主要因素。

免疫查核點抑制劑是一種用於治療癌症的藥物，其作用機制是透過抑制免疫系統細胞（例如T細胞）和癌細胞產生的特定蛋白質。它們可以單獨使用，也可以與其他癌症治療方法（例如化療和放射線治療）合併使用，以提高治療效果。此外，它們還能透過減輕疾病症狀和延長存活期來改善癌症患者的生活品質。由於免疫查核點抑制劑針對免疫系統中的特定通路，因此能夠實現更具針對性的癌症治療。與傳統化療相比，這些抑制劑毒性較低、副作用較少，且患者耐受性較好。目前，次世代定序技術的日益普及，使得識別癌細胞內特定基因突變成為可能，從而推動了全球對免疫查核點抑制劑的需求。

免疫查核點抑制劑市場趨勢：

包括黑色素瘤、肝癌、腎癌和胃癌在內的多種癌症發生率激增，是推動全球免疫查核點抑制劑需求的主要動力。此外，老年人口的成長（老年人更容易罹患這些嚴重癌症）以及肥胖症的日益普及也促進了市場成長。同時，由於酒精飲料和菸草製品消費量的增加，呼吸系統疾病的發生率也在上升。此外，不健康的飲食習慣和久坐的生活方式導致體重相關健康問題的增加，也對市場產生了積極影響。另一方面，各種遺傳性和文明病的激增，以及公眾和醫療專業人員對早期癌症診斷和治療益處的認知不斷提高，也在推動市場成長。此外，製藥公司進行的臨床試驗數量增加，以及對個人化醫療和新一代藥物及製劑的需求不斷成長，也支持市場成長。最後，主要企業專注於策略聯盟和新產品開發，旨在擴大產品系列併獲得競爭優勢，這為市場創造了良好的前景。此外，醫療基礎設施和診斷技術的顯著進步預計將進​​一步推動市場成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球免疫查核點抑制劑市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • CTLA-4抑制劑
  • PD-1抑制劑
  • PD-L1抑制劑

第7章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 市場區隔：依應用領域分類

  • 肺癌
  • 膀胱癌
  • 黑色素瘤
  • 結腸癌
  • 何傑金氏淋巴瘤
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • GSK plc
    • Merck & Co. Inc.
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Seagen Inc.
Product Code: SR112026A7221

The global immune checkpoint inhibitors market size reached USD 56.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 182.4 Billion by 2034, exhibiting a growth rate (CAGR) of 13.43% during 2026-2034. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

IMMUNE CHECKPOINT INHIBITORS MARKET TRENDS:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

KEY MARKET SEGMENTATION:

Type Insights:

  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Application Insights:

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Colorectal Cancer
  • Hodgkin Lymphoma
  • Others

Regional Insights:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global immune checkpoint inhibitors market?

2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2026-2034?

3. What are the key factors driving the global immune checkpoint inhibitors market?

4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?

5. What is the breakup of the global immune checkpoint inhibitors market based on the type?

6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?

7. What is the breakup of the global immune checkpoint inhibitors market based on the application?

8. What are the key regions in the global immune checkpoint inhibitors market?

9. Who are the key players/companies in the global immune checkpoint inhibitors market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immune Checkpoint Inhibitors Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 CTLA-4 Inhibitor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 PD-1 Inhibitor
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 PD-L1 Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bladder Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Colorectal Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hodgkin Lymphoma
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ono Pharmaceutical Co. Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Regeneron Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Seagen Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
  • Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
  • Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
  • Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players